Find Clinical Trials & Studies

Visit the Research & Education Institute

Sonrotoclax + Zanubrutinib Compared With Placebo Plus Zanubrutinib in Mantle Cell Lymphoma

I'm Interested!

Please call
1-800-641-2422

A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Sex: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Non-Hodgkin Lymphoma

Study Purpose

The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.

Principal Investigator
Changchun Deng MD

Department/Division
Cancer (Lymphoma)

UH IRB: 25-422; STUDY20250607
StudyID: BGEN1425
ClinicalTrials.gov: NCT06742996

I'm Interested!

Please call
1-800-641-2422

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422